• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脾照射治疗严重抗体介导的排斥反应。

Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.

机构信息

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

出版信息

Am J Transplant. 2016 Oct;16(10):3041-3045. doi: 10.1111/ajt.13882. Epub 2016 Jun 27.

DOI:10.1111/ajt.13882
PMID:27214874
Abstract

Patients requiring desensitization prior to renal transplantation are at risk for developing severe antibody-mediated rejection (AMR) refractory to treatment with plasmapheresis and intravenous immunoglobulin (PP/IVIg). We have previously reported success at graft salvage, long-term graft survival and protection against transplant glomerulopathy with the use of eculizumab and splenectomy in addition to PP/IVIg. Splenectomy may be an important component of this combination therapy and is itself associated with a marked reduction in donor-specific antibody (DSA) production. However, splenectomy represents a major operation, and some patients with severe AMR have comorbid conditions that substantially increase their risk of complications during and after surgery. In an effort to spare recipients the morbidity of a second operation, we used splenic irradiation in lieu of splenectomy in two incompatible live donor kidney transplant recipients with severe AMR in addition to PP/IVIg, rituximab and eculizumab. This novel approach to the treatment of severe AMR was associated with allograft salvage, excellent graft function and no short- or medium-term adverse effects of the radiation therapy. One-year surveillance biopsies did not show transplant glomerulopathy (tg) on light microscopy, but microcirculation inflammation and tg were present on electron microscopy.

摘要

需要在肾移植前进行脱敏治疗的患者有发生严重抗体介导排斥反应(AMR)的风险,这种排斥反应对血浆置换和静脉注射免疫球蛋白(PP/IVIg)治疗有抗药性。我们之前曾报道过,在使用依库珠单抗和脾切除术联合 PP/IVIg 治疗后,成功挽救了移植物、延长了移植物的长期存活率并预防了移植肾小球病。脾切除术可能是这种联合治疗的重要组成部分,它本身也与供体特异性抗体(DSA)产生的显著减少有关。然而,脾切除术是一种大手术,一些严重 AMR 的患者存在合并症,这大大增加了他们在手术期间和手术后发生并发症的风险。为了避免受者遭受第二次手术的发病率,我们在两名严重 AMR 的不相容活体供肾移植受者中,除了使用 PP/IVIg、利妥昔单抗和依库珠单抗外,还使用脾照射代替脾切除术。这种治疗严重 AMR 的新方法与移植物挽救、良好的移植物功能以及放射治疗的短期和中期不良影响无关。一年的监测活检在光镜下没有显示移植肾小球病(tg),但在电子显微镜下存在微循环炎症和 tg。

相似文献

1
Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.脾照射治疗严重抗体介导的排斥反应。
Am J Transplant. 2016 Oct;16(10):3041-3045. doi: 10.1111/ajt.13882. Epub 2016 Jun 27.
2
Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.使用抗胸腺细胞球蛋白(ATG)单药治疗以及利妥昔单抗、静脉注射免疫球蛋白和血浆置换联合治疗活检证实的急性抗体介导排斥反应:从初步经验中获得的教训
Clin Transpl. 2014:223-30.
3
Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.静脉注射免疫球蛋白和利妥昔单抗治疗慢性抗体介导的排斥反应:一项多中心、前瞻性、随机、双盲临床试验。
Am J Transplant. 2018 Apr;18(4):927-935. doi: 10.1111/ajt.14520. Epub 2017 Oct 24.
4
Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.评估托珠单抗(抗白细胞介素 6 受体单克隆抗体)作为 HLA 致敏肾移植受者慢性抗体介导排斥反应和移植肾小球病潜在治疗方法的研究。
Am J Transplant. 2017 Sep;17(9):2381-2389. doi: 10.1111/ajt.14228. Epub 2017 Mar 10.
5
Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.全淋巴照射、低剂量静脉注射免疫球蛋白和抗胸腺细胞球蛋白联合作为高敏和抗体介导排斥反应肾移植受者的挽救治疗
Clin Transpl. 2014:215-21.
6
Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.依库珠单抗和脾切除术作为 HLA 不相合肾移植后严重抗体介导排斥反应的挽救治疗
Transplantation. 2014 Oct 27;98(8):857-63. doi: 10.1097/TP.0000000000000298.
7
Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study.血浆衍生 C1 酯酶抑制剂治疗肾移植后急性抗体介导排斥反应的随机双盲安慰剂对照初步研究。
Am J Transplant. 2016 Dec;16(12):3468-3478. doi: 10.1111/ajt.13871. Epub 2016 Jun 27.
8
Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.围手术期脱敏可改善已故供体肾移植交叉配型阳性受者的预后。
Prog Transplant. 2016 Jun;26(2):157-61. doi: 10.1177/1526924816640678.
9
Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy.评估抗体清除治疗候选资格和疗效的预后工具。
Am J Transplant. 2019 Feb;19(2):381-390. doi: 10.1111/ajt.15007. Epub 2018 Aug 23.
10
Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.依库珠单抗用于需要脱敏治疗的活体供肾移植受者预防抗体介导排斥反应的安全性和疗效:一项随机试验。
Am J Transplant. 2019 Oct;19(10):2876-2888. doi: 10.1111/ajt.15364. Epub 2019 Apr 19.

引用本文的文献

1
Relationship between the microenvironment and survival in kidney transplantation: a bibliometric analysis from 2013 to 2023.肾移植中微环境与生存的关系:2013 年至 2023 年的文献计量分析。
Front Immunol. 2024 Mar 26;15:1379742. doi: 10.3389/fimmu.2024.1379742. eCollection 2024.
2
Case Report: Splenic Irradiation for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Allograft Recipients With Donor-Specific Antibodies.病例报告:脾照射治疗伴有供体特异性抗体的肾移植受者慢性活动性抗体介导排斥反应
Front Immunol. 2021 Apr 15;12:661614. doi: 10.3389/fimmu.2021.661614. eCollection 2021.
3
Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study.
次级淋巴组织与共刺激阻断抵抗排斥反应:一项灵长类动物肾移植研究。
Am J Transplant. 2019 Aug;19(8):2350-2357. doi: 10.1111/ajt.15365. Epub 2019 Apr 12.
4
Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient.固有网络:血栓性微血管病,致敏肾移植受者中凝血和补体的激活。
Transplant Rev (Orlando). 2018 Jul;32(3):119-126. doi: 10.1016/j.trre.2018.01.001. Epub 2018 Feb 10.
5
Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation.血栓素:在高度致敏的肾移植模型中使用细胞靶向抗凝剂减少血栓性微血管病
Am J Transplant. 2017 Aug;17(8):2055-2064. doi: 10.1111/ajt.14234. Epub 2017 Mar 23.